Sei Network has approved SIP-6, a key step in upgrading its Autobahn consensus mechanism within the Sei Giga project. This upgrade changes how blocks are assembled by allowing validators to process transactions concurrently, improving efficiency and reducing reliance on a single block producer. While SIP-6's approval clears a governance hurdle, the upgrade is not yet active on mainnet; further testing, audits, and a public testnet are planned before launch. The broader Sei Giga overhaul also includes other upgrades like SIP-3, aiming for enhanced performance and Ethereum Virtual Machine compatibility.
Sei Network's SIP-6 approval is noted here with Pluang's market data for context. For readers following cryptocurrency broadly, here is Pluang's market snapshot as of Nov 12, 2026 04:22 WIB: Among 50 major cryptocurrencies, 31 rose and 18 fell today. BAL (Balancer) gained 11.14% to Rp16.297 with a typical hold time of 85 days, contrasting with ONE (Harmony) which dropped 18.24% to Rp27 and sees longer holds averaging 153 days. EOS (EOS.IO) rose 8.13% to Rp12.649 with a typical hold time of 87 days.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
